New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events

Research Presented at American College of Cardiology's 67th Annual Scientific Session Reveals More Than 110,000 Cardiovascular Events a Year Could Occur in High-Risk Patients With Cardiovascular Disease who are Rejected Access Additional Study Calls for Assessment of Utilization Management Processes to Improve Access for Appropriate Patients and Prioritize Patients at the Highest Risk for Subsequent Cardiovascular Events THOUSAND OAKS, Calif., March 9, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced data from two new studies exploring barriers to access for PCSK9 inhibitors and the potential consequences of denying coverage for high-risk patients. The studies will be present...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news